Bradford L. McRae
Northwestern University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Bradford L. McRae.
Journal of Neuroimmunology | 1992
Bradford L. McRae; Mary K. Kennedy; Lit Jen Tan; Mauro C. Dal Canto; Kathleen S. Picha; Stephen D. Miller
Proteolipid protein (PLP) is a major component of the central nervous system (CNS) myelin membrane and has been shown to induce acute experimental autoimmune encephalomyelitis (EAE) in genetically susceptible animals. Here we describe conditions by which a relapsing-remitting form of EAE can be reliably induced in SJL/J mice either actively immunized with the major encephalitogenic PLP peptide, PLP13-151(S), or following adoptive transfer of PLP139-151(S)-specific T cells. The disease follows a reliable relapsing-remitting course with acute clinical signs first appearing 6-20 days after priming or transfer and relapses first appearing at 30-45 days. The initial onset of disease correlates with delayed-type hypersensitivity (DTH) reactivity specific for PLP139-151(S), in the apparent absence of T cell reactivity to the major myelin basic protein (MBP) peptide. Histologically, both the active and adoptive forms of the disease are characterized by extensive mononuclear cell infiltration and severe demyelination of the CNS. These results suggest that T cell responses specific for PLP139-151(S) are sufficient to induce clinical and histological R-EAE in SJL/J mice. This model should prove useful for examination of the cellular and molecular events involved in clinical relapses and perhaps in determining the role of PLP-specific T cell responses in multiple sclerosis (MS).
Immunological Reviews | 1995
Stephen D. Miller; Bradford L. McRae; Carol L. Vanderlugt; Kelly M. Nikcevich; Jonathan G. Pope; Louise Pope; William J. Karpus
Fig. 6 depicts a model for epitope spreading in T cell-mediated demyelination. The acute phase of disease is due to T cells specific for the initiating epitope, which can be either a determinant on the CNS target organ of the autoimmune response or a determinant on a persisting, CNS-tropic virus. The primary T cell response is responsible for the initial tissue damage by the production of proinflammatory Th1 cytokines which can affect myelination directly (Selmaj et al. 1991) and indirectly by their ability to recruit and activate macrophages to phagocytize myelin (Cammer et al. 1978). As a result of myelin damage and opening of the blood-brain-barrier during acute disease, T cells specific for endogenous epitopes on the same and/or different myelin proteins are primed and expand either in the periphery or locally in the CNS. These secondary T cells initiate an additional round of myelin destruction, leading to a clinical relapse by production of additional pro-inflammatory cytokines, similar to the bystander demyelination operative during acute disease. It will be of great interest to determine the relative contributions of local and systemic immune responses to these endogenous neuroepitopes. It is possible that local CNS presentation of endogenous neuroepitopes following acute CNS damage could be mediated by infiltrating inflammatory macrophages, activated microglial cells, endothelial cells and/or astrocytes. These tissue resident antigen presenting cells have been shown to upregulate expression of MHC class II (Sakai et al. 1986, Traugott & Lebon 1988), certain adhesion molecules (Cannella et al. 1990), and B7 costimulatory molecules (K. M. Nikcevich, J. A. Bluestone, and S. D. Miller, in preparation) in response to pro-inflammatory cytokines. The data on epitope spreading provided by the murine demyelinating disease models clearly illustrate the dynamic nature of the T cell repertoire during chronic inflammation in a specific target organ. The contribution of epitope spreading to chronic CNS demyelination could be considered to be a special case since tolerance to myelin epitopes would be expected to be inefficient due to their sequestration behind the blood-brain-barrier. However, the recent description of epitope spreading in response to pancreatic antigens in spontaneous diabetes in the NOD mouse may indicate that this phenomenon is operative in a variety of organ-specific experimental and spontaneous autoimmune diseases.(ABSTRACT TRUNCATED AT 400 WORDS)
International Reviews of Immunology | 1992
Stephen D. Miller; Litjen Tan; Louise Pope; Bradford L. McRae; William J. Karpus
The effects of neuroantigen-specific tolerance on the induction and effector stages of EAE were examined. Tolerance induced by the i.v. injection of syngeneic splenocytes coupled with purified neuroantigens or encephalitogenic peptides of MBP and PLP using ethylene carbodiimide was extremely effective in both prevention and treatment of acute and relapsing forms of EAE in Lewis rats and SJL/J mice. The unresponsiveness is rapidly-induced, dose-dependent, long-lasting, efficient, MHC class II-restricted, and exquisitely antigen-specific. This procedure targets only effector cells bearing clonotypic receptors specific for the autoantigen/autoepitope and thus does not depend upon the autoimmune response being dominated by a restricted T cell repertoire. Moreover, it does not require that the response to the autoantigen be dominated by recognition of a specific epitope(s) within a particular autoantigen, or even the identification of the specific autoantigen. The results also demonstrate the usefulness of peripheral tolerance induced by antigen-coupled syngeneic splenocytes for identifying the fine specificity of autoimmune T cell responses which appear to change during the progression of relapsing EAE. Thus, this technique offers major advantages over many other currently employed immunoregulatory strategies and is therefore relevant for establishment of therapeutic protocols for the antigen-specific treatment of human T cell-dependent autoimmune disorders.
Journal of Neuroimmunology | 2009
Chih-Liang Chin; Madhavi Pai; Peter Bousquet; Annette Schwartz; Elizabeth M. O'Connor; Christine M. Nelson; Vincent P. Hradil; Bryan F. Cox; Bradford L. McRae; Gerard B. Fox
USPIO-enhanced MRI allows non-invasive visualization of mononuclear cell infiltration into CNS lesions in MS and EAE. Herein, we show a distinct spatiotemporal pattern of CNS lesions that reveals the involvement of spino-olivocerebellar pathways in MOG-induced EAE rats using USPIO-enhanced MRI. Specifically, lesions of the inferior olives were observed primarily in the acute phase whereas lesions of cerebellum or spinal cord/brainstem were observed during the relapse phase. Further, behavioral deficits observed from these animals are consistent with the functional role of spino-olivocerebellar pathways in coordination and movement. Collectively, our results provide new insights into the pathophysiology of this animal model of MS.
Neurochemical Research | 1994
Bradford L. McRae; Stephen D. Miller
PLP 139-151(S) is the major encephalitogenic epitope of PLP in the SJL/J mouse. CD4+ T cells specific for PLP 139-151(S) induce a relapsing-remitting form of EAE which is similar to the human demyelinating disease MS in both clinical course and histopathology. We are interested in events involved in activation of autoreactive T cells and how to specifically regulate these immune response to both prevent and treat ongoing demyelinating disease. In the current study, we examined the effect of both amino acid substitutions and deletions in the native PLP 139-151(S) peptide to identify which residues are critical for immunogenicity and encephalitogenicity. Conservative and nonconservative substitutions at position 145 diminished or completely destroyed the encephalitogenic potential of the peptide without affecting the ability to recall a proliferative response in lymph node T cells primed with the native PLP 139-151(S) peptide indicating an interesting dichotomy between ability to induce T cell proliferation and ability to induce active clinical disease. In addition, tryptophan at position 144 was identified as a critical TCR contact site as a peptide containing an alanine for tryptophan at this position (A144) primed a unique population of T cells which did not cross react with the native PLP 139-151(S). In addition, A144 was unable to stimulate PLP 139-151(S)-specific T cells in vitro or to induce active relapsing EAE in vivo. The significance of these results to the potential development of new strategies for preventing and treating T cell-mediated autoimmune diseases is discussed.
Autoimmunity | 1998
Lit Jen Tan; Carol L. Vanderlugt; Bradford L. McRae; Stephen D. Miller
Our previous work has shown that specific peripheral immune tolerance induced by the intravenous administration of ECDI-fixed, antigen-coupled syngeneic splenocytes is an extremely efficient method for prevention and treatment of chronic relapsing experimental autoimmune encephalomyelitis (R-EAE) in susceptible SJL/J mice. The current study examined the mechanisms by which unresponsiveness is induced in primed encephalitogenic T cells. The results indicate that the inhibition of MBP-specific T cells by the i.v. injection of MBP-coupled splenocytes is not due to the induction of antigen-specific regulatory T cells, but rather to the induction of anergy/deletion of the effector cells. This conclusion is supported by the findings that spleen or lymph node cells isolated from MBP-tolerant mice fail to inhibit the adoptive transfer of R-EAE in cotransfer assays, and that tolerance is not inhibited by prior thymectomy or prior treatment with cyclophosphamide or anti-CD8 monoclonal antibody. In contrast, we demonstrate that splenocytes from MBP-tolerized, asymptomatic mice have a significantly reduced ability to serially transfer R-EAE to naive secondary recipients following antigen re-activation in vitro, in the first several weeks following tolerization, but that the ability to serially transfer R-EAE returns to sham tolerant control levels within 1-2 months. We also demonstrate a significantly reduced precursor frequency of MBP-specific, IL-2-producing T cells in the MBP-tolerant within three days of treatment. Collectively, the data most closely support a model wherein inhibition of MBP-specific encephalitogenic CD4+ effector T cells by i.v. injected MBP-coupled splenocytes is due to the direct induction of anergy/deletion from which they can recover over time.
Journal of Neuroimmunology | 1995
Bradford L. McRae; Kelly M. Nikcevich; William J. Karpus; Stephen D. Hurst; Stephen D. Miller
CD4+ T cells specific for PLP 139-151 induce a relapsing-remitting form of EAE which is similar to the human demyelinating disease multiple sclerosis (MS) in both clinical course and histopathology. Conservative and nonconservative amino acid substitutions were introduced at three TcR or MHC contact residues within PLP 139-151 to identify fine specificity requirements, at the polyclonal level, for stimulating naive encephalitogenic T cells and for reactivating pre-primed autoreactive T cells as measured by T cell proliferation, cytokine induction, and functional encephalitogenic potential. The results indicate that peptides with substitutions at position 145 exhibited a significantly diminished ability to induce active disease, but these substitutions had little or no effect on the ability to activate PLP 139-151-primed T cells for proliferation or disease transfer. A conservative or a nonconservative substitution at position 144 ablated both encephalitogenic potential in active and adoptive EAE models and the ability to induce proliferative responses in T cells primed to the native peptide. A nonconservative lysine for glycine, but not a conservative serine substitution, at position 146 had similar effects. In contrast to their inability to induce active EAE and stimulate in vitro proliferation of PLP 139-151-primed T cells, the Y144 and the 146 analog peptides were able to suboptimally reactivate these cells for transfer of adoptive EAE. Furthermore, the nonencephalitogenic K146 peptide was found to exacerbate in vivo induction of EAE induced by priming with a suboptimal dose of PLP 139-151. These data support the hypothesis that naive neuroantigen-specific CD4+ T cells have more stringent activation requirements than do PLP 139-151-specific T cells which have previously encountered antigen. The finding that the analog peptides induced differential patterns of cytokine production, with LT/TNF-alpha production but not IFN-gamma production correlating with full encephalitogenic potential, suggests different functional outcomes may result from differential levels of signal transduction triggered by the substituted peptides. The significance of these results to the potential development of autoimmune disease via molecular mimicry and for the development of new strategies for preventing and treating T cell-mediated autoimmune diseases is discussed.
Journal of Neuroimmunology | 1994
Stephen D. Miller; Bradford L. McRae; Kelly M. Nikcevich
FUNCTIONAL EVIDENCE FOR A ROLE FOR EPITOPE SPREADING IN THE PATHOGENESIS OF RELAPSING EAE IN SJI.JJ MICE. Steohen D. Miller. Bradford L. McRae. and Carol L. Vendedu~t. Department of Microbiology-Immunology, Northwestern University Medical School, Chicago, IL USA 60611 EAE is a T cell-mediated, inflammatory demyelinating disease of the CNS that serves as a model for MS. A relabsing-remilting form of EAE is induced in SJLJJ mice upon active immunization with, or transfer of T cells specific for, the major immunodominant determinant on proteolipld protein (PLP13g-151). EAE initiated with PLP139-151 results in a severs acute disease phase followed by mimer relapses in which responses to both intramolecular (PLP104-117 and PLP178-191) and intermolecular epitopes (MBP84-104) are observed. The PLP178-191 response is pathologic as T ceils fmm PLP139-151 primed mice reactivated in vitro with PLP178-191 transfer clinical EAE to naive recipients. Mice specifically tolerized to PLP139-151 prior to acute CNS damage fail to develop responses to the secondary PLP epitopas suggesting that epltope spreading occurs as a result of activation of peripheral T cells to neuroantigenic epltopes released from the CNS dunng acute disease• Thus T cell responses to epitopes different from that used to induce acute disease contribute to the clinical relapses. These observations have important implications for the potential use of specific immunotharepy, Le. tolerance/energy, to treat organ-specific autoimmune diseases.
Journal of Neuroimmunology | 1994
Stephen D. Miller; Bradford L. McRae; Carol L. Vanderlugt
FUNCTIONAL EVIDENCE FOR A ROLE FOR EPITOPE SPREADING IN THE PATHOGENESIS OF RELAPSING EAE IN SJI.JJ MICE. Steohen D. Miller. Bradford L. McRae. and Carol L. Vendedu~t. Department of Microbiology-Immunology, Northwestern University Medical School, Chicago, IL USA 60611 EAE is a T cell-mediated, inflammatory demyelinating disease of the CNS that serves as a model for MS. A relabsing-remilting form of EAE is induced in SJLJJ mice upon active immunization with, or transfer of T cells specific for, the major immunodominant determinant on proteolipld protein (PLP13g-151). EAE initiated with PLP139-151 results in a severs acute disease phase followed by mimer relapses in which responses to both intramolecular (PLP104-117 and PLP178-191) and intermolecular epitopes (MBP84-104) are observed. The PLP178-191 response is pathologic as T ceils fmm PLP139-151 primed mice reactivated in vitro with PLP178-191 transfer clinical EAE to naive recipients. Mice specifically tolerized to PLP139-151 prior to acute CNS damage fail to develop responses to the secondary PLP epitopas suggesting that epltope spreading occurs as a result of activation of peripheral T cells to neuroantigenic epltopes released from the CNS dunng acute disease• Thus T cell responses to epitopes different from that used to induce acute disease contribute to the clinical relapses. These observations have important implications for the potential use of specific immunotharepy, Le. tolerance/energy, to treat organ-specific autoimmune diseases.
Journal of Immunology | 1995
William J. Karpus; Nicholas W. Lukacs; Bradford L. McRae; R M Strieter; S L Kunkel; Stephen D. Miller